A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (A UNICANCER GI-PRODIGE trial).

Congress : ASCO

Authors : J. Bennouna, T. André, L. Miglianico, L. Campion, L. Mineur, Y-H Lam, S. Hiret, P. Artru, O. Bouché, F. Borde, A. Aleba, L-S Rajpar, C. Rebischung, Y. Touchefeu, P. Kavan, S. Gill , T. Asmis, C. Jouffroy-Zeller, J.F. Emile, J. Taïeb.

Experts group or program : Groupe gastro-intestinal (UCGI)


According to the IDEA trial (Shi Q et al. ASCO 2017;LBA1), 6-month adjuvant chemotherapy should remain the standard in stage III T4 or N2 colon cancer. The relatively poor survival in this high-risk subgroup (3-year disease-free survival ([DFS] rate, 66%) and the potential synergistic efficacy of 5-fluorouracil (5-FU), oxaliplatin, and irinotecan (demonstrated in stage IV colon and pancreatic cancers) suggest FOLFIRINOX as a regimen of particular interest in this setting.


En savoir plus